Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[2-13C] glucose
- Development stage
- Unknown
- Lead developer
- Joslin Diabetes Center
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
[2-13C] glucose is a stable isotope-labeled form of glucose in which the carbon-2 position is enriched with the carbon-13 (13C) isotope. It is used as a non-radioactive diagnostic tracer compound in metabolic studies to track carbohydrate metabolism in vivo (including glycolysis, glycogen synthesis, and gluconeogenesis) using techniques such as NMR spectroscopy and MRI. The compound is being utilized by the Joslin Diabetes Center in a Phase 4 clinical study to non-invasively assess post-prandial carbohydrate, hormone, and hepatic glycogen metabolism in individuals with and without post-bariatric surgery hypoglycemia (PBH).
- Other names
- D-[2-13C]glucoseD-glucose (2-13C)D-glucose-2-13CD-glucose2-13CD-glucose 2-13C[2-13C]-D-glucosedextrose-2-13cdextrose2-13cdextrose 2-13c
Beyond the preview
Go deeper on [2-13C] glucose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [2-13C] glucose.